308 related articles for article (PubMed ID: 19399841)
1. Opportunistic infections and other risks with newer multiple sclerosis therapies.
Berger JR; Houff S
Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
[TBL] [Abstract][Full Text] [Related]
2. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system infections - a potential complication of systemic immunotherapy.
Hemmer B; Frohman E; Hartung HP; Stüve O
Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal antibodies in multiple sclerosis].
Papeix C; Lubetzki C
Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
[TBL] [Abstract][Full Text] [Related]
5. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Stüve O; Marra CM; Cravens PD; Singh MP; Hu W; Lovett-Racke A; Monson NL; Phillips JT; Tervaert JW; Nash RA; Hartung HP; Kieseier BC; Racke MM; Frohman EM; Hemmer B
Arch Neurol; 2007 Feb; 64(2):169-76. PubMed ID: 17296831
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
Khalili K; White MK; Lublin F; Ferrante P; Berger JR
Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301
[TBL] [Abstract][Full Text] [Related]
7. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory therapies and the risk of opportunistic infections.
Johnson DE; Smith DA; Park BK
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):20-2. PubMed ID: 20047142
[No Abstract] [Full Text] [Related]
9. Future research directions in multiple sclerosis therapies.
Greenberg BM; Calabresi PA
Semin Neurol; 2008 Feb; 28(1):121-7. PubMed ID: 18256992
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in relapsing-remitting multiple sclerosis.
Schrijver HM
N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
[No Abstract] [Full Text] [Related]
11. Knowns and unknowns in the future of multiple sclerosis treatment.
Stüve O
J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
[TBL] [Abstract][Full Text] [Related]
12. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
13. Treatment options for multiple sclerosis: current and emerging therapies.
Gawronski KM; Rainka MM; Patel MJ; Gengo FM
Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
[TBL] [Abstract][Full Text] [Related]
14. Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair.
Carrithers MD
Curr Pharm Biotechnol; 2012 Jun; 13(8):1409-17. PubMed ID: 22339217
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: new treatment trials and emerging therapeutic targets.
DeAngelis T; Lublin F
Curr Opin Neurol; 2008 Jun; 21(3):261-71. PubMed ID: 18451708
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
Hohlfeld R; Wekerle H
Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
[TBL] [Abstract][Full Text] [Related]
17. [Immune augmenting therapy as treatment of multiple sclerosis. Warning regarding a potentially toxic alternative treatment method].
Pette M; Hartung HP; Toyka KV
Nervenarzt; 1994 Dec; 65(12):878-90. PubMed ID: 7854511
[No Abstract] [Full Text] [Related]
18. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
Hemmer B; Hartung HP
Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
[TBL] [Abstract][Full Text] [Related]
19. Evolving therapies for multiple sclerosis.
Korniychuk E; Dempster JM; O'Connor E; Alexander JS; Kelley RE; Kenner M; Menon U; Misra V; Hoque R; Gonzalez-Toledo E; Schwendimann RN; Smith S; Minagar A
Int Rev Neurobiol; 2007; 79():571-88. PubMed ID: 17531859
[TBL] [Abstract][Full Text] [Related]
20. Current evidence and therapeutic strategies for multiple sclerosis.
Wingerchuk DM
Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
